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APC = antigen-presenting cell; BTLA = B and T lymphocyte attenuator; CTLA-4 = cytotoxic T lymphocyte-associated antigen-4; DC = dendritic
cell; FOXP3 = forkhead box P3; GITR = glucocorticoid-induced tumor necrosis factor receptor; ICOS = inducible costimulatory molecule; IDO =
indoleamine 2,3-dioxygenase; IL = interleukin; TCR = T cell receptor; Th = T helper; Treg = regulatory T.
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Introduction
The discovery and characterization of new molecules that
regulate T cell activities is perhaps one of the most
intensely investigated areas in immunology. This is due to
the enormous implications and potential of this research
toward alleviating many of the scourges of the developed
world such as cancer and autoimmune diseases. Two of
the most significant developments in recent years have
been the great expansion of the number of costimulatory
ligands and receptors that belong to the extended B7 and
CD28/cytotoxic T lymphocyte-associated antigen-4
(CTLA-4) families of molecules, and the revival of
regulatory T cells. Although these topics have been
reviewed in detail elsewhere, we would like to propose a
framework for the physiological functions of the different
B7 family molecules during the distinct phases of an
immune response and to integrate this with our increased
understanding of regulatory T cells. The main theme is the
distinction between the initiation of naive T cell activation
and the regulation of effector T cell properties and
responses.
In the past decade we have come a long way in terms of
levels of complexity from the original two-signal hypothesis
[1], which proposed that T cell activation required
stimulation both via the T cell receptor (TCR) (signal 1)
and through additional costimulatory molecules (signal 2).
Instead of a simple binary on/off switch for the initiation of
a T cell response, we now understand that costimulation
orchestrates the clonal composition and features of the
T cell response. Recently, many new costimulatory
pathways have been discovered that influence the
properties of T cell responses. The discovery of novel
costimulatory ligands/receptor pairs has often been
followed by a period of uncertainty about whether
ligand–receptor engagement is stimulatory or inhibitory.
Most initial efforts are designed to distinguish between
these two properties, and a period of confusion can, and
still does, persist for some time, before a consensus is
finally reached. Although the precise functions of the many
extended B7 family members remain to be defined, it is
clear that they have distinct but also overlapping functions
(Fig. 1).
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Abstract
Whereas B7-1/B7-2 and CD28/cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) serve as the
main switches regulating the clonal composition of activated naive T cells, other B7 family members
fine-tune the expansion and properties of activated T cells. Inducible costimulatory molecule
(ICOS)–B7h promotes T-dependent antibody isotype switching and expansion of effector cells.
Effector T cells trafficking into inflamed tissues interact with antigen-presenting cells there and are
regulated by PD-1 and its ligands. B7-H3 and B7x could control the interaction between effector
T cells and the peripheral tissues. The different varieties of regulatory T cells could regulate both
naive T cell activation and effector function through costimulatory receptor/ligands.
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CD28/CTLA-4: more than just an on/off switch
The CD28/CTLA-4 and B7-1/B7-2 pathway is by far the
best-understood costimulatory pathway. Although it has
been clear for a while that CD28 helps to initiate T cell
responses and CTLA-4 is crucial in the downregulation of
responses, our recent studies have focused more on the
cell biological lifestyle of these molecules as well as their
signaling properties. Much of our understanding of the
function of CTLA-4 has been reviewed in detail recently
[2]. In brief, the temporal and spatial separation of these
two receptors is important in their function. Whereas
CTLA-4 has a much higher affinity than CD28 for their
ligands, it is not expressed constitutively on naive T cells
and is mostly localized intracellularly. After stimulation by
the T-cell antigen receptor, CD28 migrates very rapidly
into the immunological synapse from the plasma
membrane, whereas the intracellular vesicles containing
CTLA-4 need to be repositioned to the area of the
cytoplasm that is close to the synapse. Once these
vesicles have been polarized beneath the T cell–antigen-
presenting cell (APC) interface, CTLA-4 can be
translocated into the synapse to engage its ligands. We
have recently found the preferential recruitment of CTLA-4
into the synapse by B7.1, whereas B7.2 preferentially
recruits CD28 [3]. This suggests a previously
unrecognized mechanism for tuning the response
depending on the relative levels of B7.1/B7.2 expressed
on APCs.
Interestingly, the translocation of CTLA-4 into the
synapse is proportional to TCR signal strength [4].
Hence, CTLA-4 might differentially restrict the expansion
of T cells on the basis of the strength of the TCR signal
they receive. Instead of being a simple inhibitor that
attenuates T cell responses, CTLA-4 could shape the
composition and functional activity (for example T helper
1 [Th1] versus Th2) of the overall pool of T cells with
different specificities and affinities, which are activated
during the course of an immune response [2,5,6]. Indeed,
it has recently been reported that even in the absence of
Stat6 (a key signal transducer for interleukin-4 [IL-4]),
CTLA-4-deficient T cells can efficiently differentiate into
Th2 cells [7]. It was suggested that the increased signal
strength of high-affinity T cells that are no longer
restricted by CTLA-4 could result in an increased bias
towards a Th2 phenotype [7]. However, the issue of
whether increased TCR signal leads to Th2 differentiation
remains very controversial.
Figure 1
Proposed model for the function of B7 family of costimulatory ligands. 1. B7-1/B7-2 and CD28/cytotoxic T lymphocyte-associated antigen-4
(CTLA-4) regulate the clonal composition of naive T cells that become activated by antigen-bearing dendritic cells (DCs) migrating into the
lymphoid organs from the peripheral tissues. 2. After clonal expansion of naive T cells, inducible costimulatory molecule (ICOS)–B7h promotes the
T-dependent antibody isotype switching and expansion of effector T cells when the differentiated T helper cells (Th) migrate into the follicles and
help to activate germinal-centre B cells. 3. Effector T cells (Teff) trafficking into inflamed tissues interact with antigen-presenting cells such as
macrophages and are regulated by programmed death (PD)-1 and its ligands (PDLs). 4. B7-H3 and B7x could be the last-ditch regulators and
control the interaction between Teff and the peripheral tissues. BTLA, B and T lymphocyte attenuator.
T cell area
T
Antigen
bearing
DC
Afferent lymphatics
MΦ
Eosinophils
Neutrophils
B
Efferent lymphatics
Follicle
B
l
o
o
d
 
v
e
s
s
e
l
s
Tnaïve
Lymph nodes
Antigen capturing DC
1
2
Th
T T T
T
T
B cell
3
T
T
T T
T
Teff
4
B7.1/B7.2 - 
CD28/CTLA-4
ICOS - B7h
Peripheral tissues
T T T
PD1 - PDL1/PDL2
Teff
B7x/B7H3 - ? BTLA?
Tissue fibroblasts
T
T210
Arthritis Research & Therapy    Vol 6 No 5 Loke and Allison
Although the inhibitory effects of CTLA-4 are clear, a
variety of endogenous versus exogenous mechanisms
have been proposed. Whereas we have focused on
understanding the cell-endogenous mechanisms of
inhibition [2], others have suggested that CTLA-4 has a
role in immunosuppression by CD4+CD25+ regulatory
T cells (Treg cells; discussed below). It has also been
suggested that CTLA-4 has a role in the induction of
anergic T cells [8] that could in turn be suppressive [9].
These mechanisms are not necessarily mutually exclusive
and might act in concert.
More recently, a splice variant of mouse CTLA-4 was
discovered that has a fully intact open reading frame
encoding a transmembrane isoform that lacks the B7-
1/B7-2-binding domain (liCTLA-4) as a result of skipping
exon 2 [10]. There is an association between the
autoimmune susceptible strain of NOD mice with a
fourfold decrease in the expression of liCTLA-4, which is
in turn associated with a silent mutation in exon 2. A
ligand-independent isoform for CD28 has also been
reported [11]. Future studies will have to reconcile the
potential functions of these ligand-independent forms,
with our recent findings that ligand binding is required for
localizing CTLA-4 to the immunological synapse [3].
Perhaps liCTLA-4 provides a ‘tonic’ inhibitory signal that
decreases the T cell activation threshold during the
transient non-specific interactions between T cells and
dendritic cells (DCs) that occur continuously in the lymph
nodes.
ICOS–B7h: antibody production, effector cell
differentiation and function
Inducible costimulatory molecule (ICOS) and B7h were
the first extended family members of the CD28/B7
costimulatory receptor–ligand pairs to be discovered after
almost a decade. This pair has been the subject of intense
study over the past few years [12,13]. The phenotype of
B7h-deficient and ICOS-deficient mice clearly indicates
that they are a unique receptor–ligand pair that have a
positive costimulatory effect. The most striking phenotype
of these mice is a defect in T-dependent antibody isotype
switching and germinal center formation. CD40 and
CD40 ligand (CD40L) could be important in stabilizing the
ICOS–B7h interaction between T cells and naive B cells
and in promoting germinal center formation [14].
Interestingly, a homozygous mutation of ICOS in human
patients leads to an immunodeficiency syndrome
characterized by severe reduction in all immunoglobulin
subclasses [12]. This is consistent with the hypothesis
that the main function of ICOS–B7h is to regulate B cell
differentiation, class switching and B cell memory
responses through germinal center formation.
Although ICOS was originally perceived to costimulate
Th2 responses [15], studies with a variety of infectious
pathogens have shown that both Th1 and Th2 cytokines
were sometimes (although not consistently) altered [12].
The most consistent findings from studies involving
antibody blockade and gene-deficient mice were a
decrease in T-dependent antibody isotypes (such as
IgG1) and no significant differences in the CD8+ cytotoxic
T lymphocyte responses. The ICOS–B7h interaction has
also been shown to influence the outcome of
pathogenesis in several complex autoimmune diseases,
transplants, allergy, and tumor models [12,13]. However, a
clear consensus on how and why interfering with
ICOS–B7h interactions influences the outcome in these
models has not emerged. There is no consistent switch or
selective decrease in Th1 versus Th2 cytokines when
different systems are compared. A likely explanation is the
temporal or kinetic differences between these different
experimental models, because adoptive transfer studies
have suggested that ICOS–B7h serves to enhance the
primary and not the secondary T cell responses in vivo
[16,17].
Is there another positive costimulatory
receptor for PD-L1 and PD-L2?
Although PD-1 was discovered more than 10 years ago
now, it was not until its ligands were cloned and found to
be homologous to the B7 family members that it was
recognized as a costimulatory molecule. The expression
profile of both the ligands [13] and PD-1 would suggest
that this interaction is important in regulating effector T cell
responses in the peripheral tissues by professional APCs
such as DCs, macrophages and also endothelial cells
[18–23]. One of the more interesting controversies has
been the question of whether PD-L1 (or B7-H1) and PD-
L2 (or B7-DC) are costimulatory or inhibitory ligands.
Although the autoimmune phenotype of the PD-1-deficient
mice clearly suggests an inhibitory function for this
receptor [13], evidence has accumulated for an
undiscovered second stimulatory receptor. Site-directed
point mutations in both PD-L1 and PD-L2 were found to
abrogate binding to PD-1, but retained costimulatory
activity when expressed as Ig fusion proteins [24]. These
mutant Ig-fusion proteins could costimulate both PD-1–/–
and wild-type T cells. In addition, two other reports have
made the observation that PD-L2–Ig fusion proteins could
bind and costimulate PD-1-deficient T cells [25,26].
However, a costimulatory function for PD-L1 would not be
consistent with the phenotype reported for the PD-L1-
deficient mice [27]. PD-L1-deficient mice accumulate
CD8+ T cells in the liver that could cause enhanced
autoimmune hepatitis when experimentally challenged, but
did not develop spontaneous liver disease [27]. This
phenotype is consistent with the observation that PD-L1 is
highly expressed on liver Kupffer cells and to a smaller
extent on sinusoidal endothelial cells, and its expression
can inhibit activated T cells [21]. Although this report211
implicated an inhibitory role for PD-L1 in the deletion or
regulation of CD8+ T cells, dendritic cells from PD-L2-
deficient mice have a diminished capacity to activate
CD4+ T cells [26]. No other phenotypic effects were
described for the PD-L2-deficient animals in this study.
The issue of whether PD-L1 and PD-L2 are costimulatory
or inhibitory is therefore still unresolved.
On the basis of observations that PD-L1 and PD-L2 are
differentially regulated by Th1 and Th2 cytokines
[20,22,23], we speculated that PD-L1 and PD-L2 might
differentially regulate Th1 and Th2 cells [22]. In support of
this hypothesis, it has recently been shown that antibody
blockade of PD-L2 enhanced the Th2 response in an
allergic asthma model [28]. However, reports on PD-L1
blockade do not provide a clear consensus: there have
been reports of both positive [29] and negative [18,30]
functions of this molecule. Future analysis of the gene-
deficient mice, perhaps with infectious disease models
that drive Th1 and Th2 responses, should be able to
determine whether there is differential regulation of Th1
and Th2 cells by these ligands.
B7-H3 and B7x: last-ditch regulators of the
peripheral tissues?
B7-H3 and B7x (also called B7-H4 and B7-S1) are the
most recently discovered B7 family members. From our
phylogenetic analyses we found that B7-H3 and B7x fall
into the same B7 family subgroup. Because they are more
similar to each other than to the other B7 familiy members,
we have speculated that they might share one or more
common receptors. B7-H3 was originally cloned from
human DCs [31]. It has a very general mRNA expression
(for example heart, kidney, and testes), although the cell
types expressing B7-H3 in these tissues remain to be
established. The receptor for B7-H3 is still unknown but
seems to be rapidly and transiently upregulated on T cells
after activation. Although B7-H3 was originally reported to
costimulate T cell proliferation, interferon-γ production and
Th1 responses, the B7-H3-deficient mice have an
enhanced interferon-γ response in airway inflammation
experiments, suggesting an inhibitory role [32]. As with
PD-L1 and PD-L2, these conflicting observations for B7-
H3 should, it is hoped, be resolved by the identification of
the co-receptor and detailed studies of the cell biology
and signaling properties of these molecules.
We and others have recently identified another member of
the B7 family, B7x [33], also called B7-S1 [34] and B7-
H4 [35]. In brief, B7x also seems to have a much wider
tissue distribution than the original B7-1 and B7-2
molecules, similar to that of B7-H3. It is expressed in
several peripheral non-lymphoid tissues including the lung,
testis, pancreas, kidney, and liver. It is also expressed in
several tumor cell lines. In vitro experiments in our
laboratory as in others show that B7x can inhibit
proliferation and cytokine production by both CD4 and
CD8 T cells [33–35] In vivo, administration of anti-B7x
antibodies has been shown to exacerbate experimental
autoimmune encephalomyelitis [34]. Taken together, these
observations suggest that B7x inhibits T cell responses.
However, the complexities that have previously been
observed for the PD-1 ligands and for B7-H3 prevent us
from completely ruling out the possibility that B7x might be
costimulatory under certain conditions. Currently, a
candidate for the B7x counter-receptor is B and T
lymphocyte attenuator (BTLA) [36], because T cells from
BTLA-deficient mice fail to bind B7x-Ig. However, receptor
binding assays to prove the pairing of B7x and BTLA
formally remain to be performed.
Recently, immunohistological studies have shown that B7x
was expressed in most ovarian cancers and in some lung
cancer tissue, but not in any melanoma samples [37]. B7x
expression was found mainly in cytoplasm and plasma
membrane of the lung and ovarian cancer cells
themselves. The expression of B7x makes it an attractive
potential target for enhancing the anti-tumor immune
response, perhaps in conjunction with CTLA-4 blockade.
We have already demonstrated the therapeutic potential
of CTLA-4 blockade as anti-tumor therapy in human
clinical trials [38,39]. PD-L1/B7-H1 has also been
proposed to be a good target for boosting anti-tumor
immunity [40,41]. Future studies will determine whether
B7x is important in tumor immune evasion and would also
be a suitable target of anti-tumor immunotherapy.
Costimulation and various regulatory T cells:
FOXP3, GITR, and ‘anti-suppression’
To understand how the T cell response is coordinated as
a whole, it is important to integrate our understanding of
‘regulatory’ T cells with the emerging concepts in
costimulation. At least two different forms of suppressor T
cells seem to be recognized at the moment. The first are
the so-called ‘natural’ regulatory CD4+CD25+ (Treg) class
because they seem to differentiate from a thymic lineage
and are absent from mice that have been thymectomized
at an early age [42]. There are significant numbers of
these cells in most secondary lymphoid organs where they
could prevent the priming of self-reactive naive T cells.
Suppressors of the second form are considered to come
from an ‘induced’ type (Tr1), having arisen as a result of
priming under specific conditions, instead of being
preselected to be suppressors through their TCR
[43–45]. The key phenotype of these induced
suppressors is the secretion of IL-10 [46], and ICOS is
potentially important in the function of these cells [47]. T
cells that express high levels of ICOS are often found to
co-express IL-10 [48].
The discovery of forkhead box P3 (FOXP3) as a key
transcription factor in controlling the differentiation of
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thymic-lineage-dependent ‘natural’ CD4+CD25+ Treg cells
[49–51] has potentially provided a marker to differentiate
between Treg cells and Tr1 cells. However, it is important
not to exclude the possibility that FOXP3+ ‘natural’ Treg
cells can also be ‘induced’ for specific functions under
certain conditions. Future work should determine whether
these two populations of suppressors can substitute for
each other’s functions. One interesting possibility is that
CD4+CD25+ Treg cells serve primarily to regulate naive T
cell priming in the secondary lymphoid organs, whereas
Tr1 cells serve to dampen effector T cell responses in the
periphery.
With the discovery of multiple layers of immune regulation
it is sometimes daunting to consider how an immune
response can be triggered at all, even when B7-1 and B7-2
are expressed on dendritic cells. Recently, the emergence
of ‘anti-suppression’ mechanisms has been proposed to
explain part of this puzzle. Two forms of anti-suppression
have been described so far. The expression of IL-6 by
DCs activated through Toll-like receptors has been shown
to make responder T cells refractory to suppression by
suppressive T cells [52]. In contrast, the recently
discovered interaction between glucocorticoid-induced
tumor necrosis factor receptor (GITR) and its ligand,
GITRL, is thought to abrogate suppression by turning off
the ability of suppressor T cells to perform their function
[53–55], although this is controversial because GITR is
also expressed on recently activated T cells. Antibodies
against GITR have been suggested to reverse
suppression by CD4+CD25+ cells; they seem to activate
signaling into the CD4+CD25+ cells and can shut down
their function [53]. The addition of recombinant GITRL has
the same effect of reversing suppression [55]. Although
the GITR-deficient mice have enhanced T cell responses,
they are viable and fertile with no reported signs of
autoimmunity, perhaps because of an increased sensitivity
to activation-induced cell death. Future work should
establish how physiologically important these anti-
suppression mechanisms are in controlling the activation
of naive T cells in vivo.
When ligands become receptors: the
induction of indoleamine 2,3-dioxygenase
(IDO) by Treg cells expressing CTLA-4
The linkage between regulatory T cells and costimulation
has also come from interesting reports suggesting that
some of the B7 family of costimulatory ligands can serve
as receptors and transduce signals that change the
behaviour of APCs. A naturally occurring human IgM
antibody was found to crosslink PD-L2 and to increase
antigen presentation and IL-12 production by DCs [56].
After treatment with this antibody either in vitro or in vivo,
there was increased DC trafficking to the lymph nodes,
suggesting that PD-L2 engagement could enhance DC
function.
More importantly, a relationship has been proposed to
exist between CTLA-4 engagement of B7-1 and B7-2 and
the induction of the tryptophan-catabolizing enzyme IDO
[57], which has been previously shown to have a key role
in regulating fetal tolerance during pregnancy [58]. CTLA4
Ig fusion proteins have been widely used as a reagent to
suppress allograft or xenograft rejection in mouse models
of cardiac, liver, and islet transplantation [59]. It has
recently been suggested that the major mechanism of
action for CTLA4 Ig is not necessarily through the
blockade of costimulation of T cells but through the
induction of IDO production and tryptophan catabolism as
a mechanism regulating T cell activation by increasing
apoptosis [60]. It was subsequently shown that
CD4+CD25+ Treg cells could induce IDO upregulation and
tryptophan catabolism in dendritic cells through a B7-
1/B7-2-dependent pathway [57], perhaps as a result of
increased surface expression of CTLA-4. The conclusions
from these experiments on mice were supported by
experiments  in vitro with human cells showing similar
results [61]. Although these studies are interesting, how
and why the CD28 engagement of B7-1 and B7-2 does
not also induce immune suppression through IDO are
important questions to be answered. It also remains
difficult to separate in vivo the effects of costimulatory
blockade in the T cells with immune suppression through
IDO from the APCs.
Conclusions
We are at very different stages in our understanding of the
various costimulatory molecule–ligand pairs. With the
original costimulatory ligand pairs of B7-1/B7-2 and
CD28/CTLA-4 there is now a fairly detailed biochemical
and cell biological understanding of their properties and
their physiological functions. The molecular and signaling
pathways of the more recently discovered costimulatory
receptors such as ICOS and PD-1 have only just begun to
be examined, although we are beginning to understand
their  in vivo functions through the analysis of gene-
deficient mice and antibody blockade experiments. With
the orphan costimulatory ligands (B7-H3 and B7x) and
their potential partners (BTLA), we still know very little
about their physiological roles or the signaling pathways
that they control. Finally, our understanding of how
regulatory T cells develop and perform their function is
beginning to coincide with our understanding of
costimulatory modulation of T cell activation. Future efforts
should lead to greater convergence of these two topical
subjects.
Currently we favor the view that CD28 and CTLA-4 are
the major switches that regulate the early outcome of TCR
engagement during naive T cell activation but can also
shape the composition and function of the primed T cell
pool. After naive T cells have been primed and begin to
undergo clonal expansion, the other B7 family members
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and their receptors serve as ‘lenses’ to fine-tune the
differentiation and function of the activated T cells.
ICOS–B7h interaction could be important in amplifying
the primary expansion and promoting the differentiation of
effector T cells, perhaps Th2 cells and Tr1 cells. But more
importantly, ICOS/B7h has a crucial role in stabilizing T–B
interactions and for helping T-dependent antibody isotype
switching in B cells. Effector T cells that leave the
secondary lymphoid organs and penetrate back into the
inflamed tissues are further regulated by interactions
between PD-1 and its ligands, especially when the T cells
interact with professional APCs in these tissues such as
inflammatory macrophages, dendritic cells, and possibly
endothelial cells.
Although PD-1 is clearly an inhibitory receptor, there is
controversy over whether its ligands PD-L1 and PD-L2 are
costimulatory or inhibitory. Differential regulation of PD-L1
and L2 by Th1 and Th2 cytokines also suggests
differential function in regulating Th1 and Th2 responses
in the peripheral tissues by inflammatory APCs. Finally,
B7-H3 and B7x could be important in controlling the
interactions between effector T cells and non-APCs in the
peripheral tissues. Similarly to the distinct properties of
the different costimulatory ligands, the different varieties of
regulatory T cell could have different roles in coordinating
the initiation phase in the secondary lymphoid organs, as
opposed to the effector functions of T cells in inflamed
tissues. Regulatory molecules such as IL-6 and GITR
might reverse the action of Treg cells by making the
responder cells no longer responsive to suppression or by
shutting off the Treg cells. Finally, the induction of
tryptophan catabolism in dendritic cells by Treg cells could
represent a novel mechanism of regulation through
starvation-induced apoptosis.
The intense efforts towards understanding T cell
regulatory molecules over the 20 years since the discovery
of the TCR have shaped much of our understanding today
regarding the immune system. After such a great amount
of research on this one cell type, there seems to be no
shortage of new mechanisms to be discovered. Some of
the new challenges for this century will be the translation
of this knowledge into therapies that can substantially
improve human health.
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